PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$107.55
as of July 15, 2026 -
YTD RETURNS5.74%
as of July 15, 2026 -
Total Net Assets$918.27M
as of July 15, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 07/15/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
19.85 |
182,261,755 |
|
NVS |
Novartis Ag |
10.40 |
95,518,680 |
|
MRK |
Merck & Co Inc |
9.64 |
88,480,162 |
|
NVO |
Novo Nordisk A/S |
5.76 |
52,870,643 |
|
PFE |
Pfizer Inc |
4.73 |
43,401,840 |
|
BMY |
Bristol-Myers Squibb Co |
4.63 |
42,550,156 |
|
ABBV |
Abbvie Inc |
4.52 |
41,460,619 |
|
MCK |
Mckesson Corp |
4.42 |
40,590,756 |
|
GSK |
Gsk Plc |
4.41 |
40,509,878 |
|
JNJ |
Johnson & Johnson |
4.31 |
39,569,887 |
|
SNY |
Sanofi Sa/France |
4.17 |
38,301,288 |
|
AZN |
Astrazeneca Plc |
3.91 |
35,945,480 |
|
COR |
Cencora Inc |
3.58 |
32,858,770 |
|
HLN |
Haleon Plc |
3.29 |
30,175,295 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
3.00 |
27,532,414 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
2.90 |
26,612,560 |
|
ZTS |
Zoetis Inc |
2.21 |
20,335,212 |
|
VTRS |
Viatris Inc |
1.17 |
10,745,723 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.09 |
10,026,551 |
|
AXSM |
Axsome Therapeutics Inc |
0.76 |
6,959,629 |
|
CORT |
Corcept Therapeutics Inc |
0.53 |
4,849,678 |
|
ELAN |
Elanco Animal Health Inc |
0.37 |
3,424,480 |
|
OGN |
Organon & Co |
0.23 |
2,132,661 |
|
BHC |
Bausch Health Cos Inc |
0.10 |
907,085 |
|
PRGO |
Perrigo Co Plc |
0.06 |
548,425 |
|
-USD CASH- |
-- |
0.00 |
6,351 |
|
-- |
Other/Cash |
-0.03 |
-305,554 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 06/30/2026
-
Sector
% of Net Assets -
Health Care
99.51 -
Other/Cash
0.49
Country Weightings (%) as at 06/30/2026
-
Country
% of Net Assets -
United States
61.75 -
United Kingdom
11.84 -
Switzerland
10.63 -
Denmark
5.37 -
France
4.00 -
Israel
3.06 -
Japan
2.87 -
Other/Cash
0.49
Fees
Distributions
as of 07/15/2026
Quarterly
1.94%
2.32%
2.02%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency